Supported Research

Search by keyword:


Full Archive


Modeling hematopoietic clonal evolution in Fanconi anemia

2019 | Research Grant | George Q. Daley, Grant Rowe

FA confers a high risk of developing leukemia at a young age, and patients with FA who develop leukemia are difficult to treat with have poor long-term outcomes. Leukemia develops as a consequence of the acquisition of genetic mutations within blood stem cells in the bone marrow that cooperate to dr…

Squamous Cell Carcinoma Chemoprevention Phase 1

2019 | Research Grant | Markus Grompe

Head and neck cancer is a major issue for the FA population. There is no suitable preclinical model to study potential strategies for preventing or delaying squamous cell carcinoma in FA. Using a cancer-prone mouse model developed by a lab in the United Kingdom, researchers will test small molecules…

Treating Fanconi Anemia Cancer with Proton Precision Therapy

2019 | Research Grant | Mathieu Sertorio, Yi Zheng

Treatment of blood complications in FA kids using bone marrow transplantation has seen great improvement over the past decade. However, after a successful bone marrow transplantation, those kids affected with FA must now face nonblood malignancies in subsequence adolescent life which defy convention…

Development of a safe, completely non-genotoxic anti-Kit antibody-based conditioning regimen for hematopoietic stem cell transplantation in Fanconi Anemia

2018 | Research Grant | Agnieszka Czechowicz

Bone marrow transplantation has been used for 60+ years to treat >1,000,000 patients suffering from many types of blood or immune diseases, and this therapy is the best current treatment for FA patients experiencing blood problems. This procedure relies on replacing sick blood-forming stem cells in …

Direct in vivo gene correction of hematopoietic stem cell populations in Fanconi anemia

2018 | Research Grant | Kevin Haworth, Hans-Peter Kiem

Fanconi Anemia (FA) is characterized by fragile bone marrow and the inability to repair DNA damage which accumulates in repopulating stem cells, leading to marrow failure. Current treatments often involve bone marrow transplantation however the majority of patients will not have an appropriately mat…

Identification of Novel Therapeutic Targets against Fanconi Anemia-associated Squamous Cell Carcinoma

2018 | Research Grant | Agata Smogorzewska

Fanconi anemia patients are dramatically predisposed to early-onset and aggressive head, neck, and anogenital squamous cell carcinoma (SCC). Treating Fanconi SCCs is challenging due to high-frequency recurrence and patient chemosensitivity, yielding an average survival rate of

Phase 1: Pilot Study of Metformin for Patients with Fanconi Anemia

2018 | Clinical Trial | Akiko Shimamura

Low blood counts due to bone marrow failure are a common complication of Fanconi anemia (FA) which affect health and quality of life. Metformin improves blood counts in mice with FA and may protect against DNA damage. Laboratory studies suggest that Metformin may be protective against aldehydes, whi…

Quercetin chemoprevention for Squamous cell carcinoma in patients with Fanconi anemia

2018 | Clinical Trial | Parinda Mehta

Excessive toxicity from chemotherapy and radiation makes treatment for SCC in FA quite challenging and leads to dismal outcomes, in fact fatal outcomes in most patients. Thus, there is clearly a need for a new approach both for prevention and/or treatment that has fewer and less severe side effects.…

Reducing the burden of squamous cell carcinoma in Fanconi anemia - 2018

2018 | Service Grant | Ralf Dietrich, Eunike Velleuer

Eighty percent of FA patients survive beyond age 20, carry a high risk for squamous cell carcinoma (SCC) of the oropharyngeal and anogenital regions connected with high morbidity and mortality. In addition to intrinsic genetic instability, HSCT and a number of other factors contribute to the pathoge…

The Fanconi Anemia Cancer Translational Resource

2018 | Research Grant | Raymond Monnat, Jr.

Fanconi anemia (FA) patients are at exceptionally high risk of developing epithelial cancers. We aim to identify features of these cancers that provide new insight into their origins, and better ways to treat these cancers in the context of FA patients. As part of this Resource we will develop and c…

Use of triplex-forming PNAs as a strategy for correction of the FA phenotype (continued)

2018 | Research Grant | Peter Glazer, Gary Kupfer

As a monogenic blood disorder with potential survival disadvantage, Fanconi anemia has long been considered an attractive target for conventional gene therapy but success has been elusive. Consequently, there has been increasing interest in developing techniques to catalyze correction of the disease…

Defining tractable approaches for gene editing of Fanconi Anemia hematopoietic stem cells

2017 | Research Grant | Jacob Corn

My lab has developed a rapid and efficacious Cas9-based approach to introduce programmed sequence changes to human cells with ease. This work takes advantage of our discovery that Cas9 is extremely long-lived on its target DNA, yet releases a flap of single stranded DNA after cleavage. By using Cas…